Welcome to our dedicated page for Selectis Health SEC filings (Ticker: GBCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Selectis Health, Inc. (GBCS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Selectis Health’s healthcare facility portfolio, financing arrangements, and corporate governance decisions, complementing the company’s press releases.
For Selectis Health, Current Reports on Form 8-K are particularly important. Recent 8-K filings have disclosed material events such as definitive purchase and sale agreements for skilled nursing facilities in Georgia, related operations transfer agreements, and the terms of a Third Amended and Restated Allonge and Modification Agreement for senior secured promissory notes. Other 8-Ks describe appointments of new board members and changes in leadership roles, providing context on the company’s governance and oversight.
Investors can also review Selectis Health’s periodic reports, such as Forms 10-Q and 10-K, which include discussions of healthcare operations, facility performance, and revisions to previously issued financial statements, as referenced in the company’s communications. These filings may address topics like revenue from healthcare operations, operating expenses, and revisions related to accounting for healthcare revenue and intercompany transactions.
On Stock Titan, AI-powered summaries help explain the key points in lengthy filings, highlighting items such as transaction terms, maturity extensions for debt, warrant modifications, and board appointments. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports, when filed, can be used to track equity dealings by directors and officers. This page is intended as a centralized view of Selectis Health’s regulatory history, enabling users to quickly understand the substance of each filing without reading every page in full.
Selectis Health, Inc. (GBCS) reported Q3 2025 results showing healthcare revenue of $10,839,954 versus $10,016,416 a year ago, driven by higher Medicaid rates in Georgia and Oklahoma. Net income was $752,365 compared to a prior-year loss, aided by $659,923 from employee retention credits and higher other income.
For the nine months, the company recorded a net loss of $211,631 versus $1,847,498 last year, with interest expense lower on reduced debt. Liquidity remains tight: cash was $417,125 and restricted cash $806,886 as of September 30, 2025, with a working capital deficit of approximately $16.3 million. Total debt, net of discount, was $31,126,545, and the company disclosed noncompliance with two loan covenants, classifying related amounts as current. Management noted substantial doubt about continuing as a going concern and outlined plans to increase occupancy and rates, control costs, and seek capital. As of November 12, 2025, common shares outstanding were 3,067,059.